{
  "text": "Mucopolysaccharidosis III and GM1 gangliosidosis are comorbid conditions.",
  "status": "processed",
  "additional_info": "{\"supportingPapers\": [{\"title\": \"Lysosomal Storage Disorders in the Newborn\", \"authors\": [{\"name\": \"Orna Staretz\\u2010Chacham\", \"hIndex\": 16}, {\"name\": \"Tess C. Lang\", \"hIndex\": 7}, {\"name\": \"Mary E. LaMarca\", \"hIndex\": 21}, {\"name\": \"Donna M. Krasnewich\", \"hIndex\": 42}], \"link\": \"https://europepmc.org/articles/pmc2768319?pdf=render\", \"relevance\": 0.2, \"weight_score\": 0.4775, \"excerpts\": [\"GM1 gangliosidosis type 1, infantile form, can also present with developmental delay. Denis et al described a female newborn who, by the third day of life, was hypotonic with a poor suck but had hyper-reflexia.\", \"Cardiomyopathy may be associated with several other LSDs including Fabry disease, Gaucher disease, Niemann-Pick type A, I-cell disease, GM1 gangliosidosis, Sandhoff disease, sialidosis, galactosialidosis, infantile sialic acid storage disease (ISSD), and Schindler disease, although these generally do not manifest in the newborn.\"], \"explanations\": [\"The paper discusses GM1 gangliosidosis and mucopolysaccharidosis (MPS) in the context of lysosomal storage disorders, but it does not mention any comorbidity between Mucopolysaccharidosis III and GM1 gangliosidosis.\", \"The paper provides detailed descriptions of various lysosomal storage disorders, including GM1 gangliosidosis and different types of MPS, but it does not establish a direct link or comorbidity between MPS III and GM1 gangliosidosis.\"], \"citations\": [{\"text\": \"GM1 gangliosidosis type 1, infantile form, can also present with developmental delay. Denis et al described a female newborn who, by the third day of life, was hypotonic with a poor suck but had hyper-reflexia.\", \"page\": 10, \"citation\": \"TY  - JOUR\\n        TI  - Lysosomal Storage Disorders in the Newborn\\n        AU  - Orna Staretz\\u2010Chacham and Tess C. Lang and Mary E. LaMarca and Donna M. Krasnewich\\n        PY  - 2009\\n        JO  - PEDIATRICS\\n        UR  - https://europepmc.org/articles/pmc2768319?pdf=render\\n        SP  - 10\\n        ER  -\"}, {\"text\": \"Cardiomyopathy may be associated with several other LSDs including Fabry disease, Gaucher disease, Niemann-Pick type A, I-cell disease, GM1 gangliosidosis, Sandhoff disease, sialidosis, galactosialidosis, infantile sialic acid storage disease (ISSD), and Schindler disease, although these generally do not manifest in the newborn.\", \"page\": 12, \"citation\": \"TY  - JOUR\\n        TI  - Lysosomal Storage Disorders in the Newborn\\n        AU  - Orna Staretz\\u2010Chacham and Tess C. Lang and Mary E. LaMarca and Donna M. Krasnewich\\n        PY  - 2009\\n        JO  - PEDIATRICS\\n        UR  - https://europepmc.org/articles/pmc2768319?pdf=render\\n        SP  - 12\\n        ER  -\"}]}], \"nonRelevantPapers\": [{\"title\": \"Sanfilippo syndrome: causes, consequences, and treatments\", \"authors\": [{\"name\": \"Anthony O. Fedele\", \"hIndex\": 11}], \"link\": \"https://www.dovepress.com/getfile.php?fileID=28149\", \"explanation\": \"The paper is focused solely on Mucopolysaccharidosis III (Sanfilippo syndrome) and does not mention GM1 gangliosidosis or any potential comorbidity between the two conditions. Therefore, it does not provide any information relevant to the claim that Mucopolysaccharidosis III and GM1 gangliosidosis are comorbid conditions.\"}, {\"title\": \"GM1-gangliosidosis (genetic beta-galactosidase deficiency): identification of four mutations in different clinical phenotypes among Japanese patients.\", \"authors\": [{\"name\": \"Junji Nishimoto\", \"hIndex\": 11}, {\"name\": \"Eiji Nanba\", \"hIndex\": 43}, {\"name\": \"Koji Inui\", \"hIndex\": 55}, {\"name\": \"Seigo Okada\", \"hIndex\": 13}], \"link\": \"https://pubmed.ncbi.nlm.nih.gov/1909089\", \"explanation\": \"The paper exclusively discusses GM1-gangliosidosis, its genetic mutations, and phenotypic expressions. It does not address Mucopolysaccharidosis III or any potential comorbidity between the two conditions, making it irrelevant to the claim.\"}, {\"title\": \"Autism medical comorbidities\", \"authors\": [{\"name\": \"Mohammed Al\\u2010Biltagi\", \"hIndex\": 20}], \"link\": \"https://doi.org/10.5409/wjcp.v10.i3.15\", \"explanation\": \"The paper discusses medical comorbidities in children with autism spectrum disorders (ASD) and does not mention Mucopolysaccharidosis III or GM1 gangliosidosis. There is no information provided about the comorbidity of these two specific conditions, making the paper irrelevant to the claim.\"}, {\"title\": \"Epidemiology of mucopolysaccharidoses\", \"authors\": [{\"name\": \"Shaukat Khan\", \"hIndex\": 25}, {\"name\": \"Hira Peracha\", \"hIndex\": 4}, {\"name\": \"Diana Ballhausen\", \"hIndex\": 26}, {\"name\": \"Alfred Wiesbauer\", \"hIndex\": 1}], \"link\": \"https://europepmc.org/articles/pmc5653283?pdf=render\", \"explanation\": \"The paper does not address the claim that Mucopolysaccharidosis III and GM1 gangliosidosis are comorbid conditions. It focuses on the epidemiology and genetic mutations of various MPS types and GM1 gangliosidosis separately, without discussing any potential comorbidity or co-occurrence between these two specific conditions.\"}, {\"title\": \"Niemann-Pick disease type C\", \"authors\": [{\"name\": \"Marie T. Vanier\", \"hIndex\": 0}], \"link\": \"https://ojrd.biomedcentral.com/counter/pdf/10.1186/1750-1172-5-16\", \"explanation\": \"The paper is focused on Niemann-Pick disease type C and does not mention Mucopolysaccharidosis III or GM1 gangliosidosis, nor does it discuss any comorbid conditions involving these diseases. Therefore, it is not relevant to the claim that Mucopolysaccharidosis III and GM1 gangliosidosis are comorbid conditions.\"}, {\"title\": \"The cell biology of lysosomal storage disorders\", \"authors\": [{\"name\": \"Anthony H. Futerman\", \"hIndex\": 77}, {\"name\": \"Gerrit van Meer\", \"hIndex\": 66}], \"link\": \"https://dspace.library.uu.nl/bitstream/handle/1874/14471/2.Futerman2004%20pp554-65.pdf?sequence=1&isAllowed=y\", \"explanation\": \"The paper discusses lysosomal storage disorders in general, focusing on the biochemical and cellular pathways affected by these disorders. However, it does not specifically address Mucopolysaccharidosis III or GM1 gangliosidosis, nor does it discuss any potential comorbidity between these two conditions. Therefore, the content is not relevant to the claim about the comorbidity of Mucopolysaccharidosis III and GM1 gangliosidosis.\"}, {\"title\": \"Current and Future Prospects for Gene Therapy for Rare Genetic Diseases Affecting the Brain and Spinal Cord\", \"authors\": [{\"name\": \"Thomas Leth Jensen\", \"hIndex\": 2}, {\"name\": \"Casper R. G\\u00f8tzsche\", \"hIndex\": 14}, {\"name\": \"David P.D. Woldbye\", \"hIndex\": 40}], \"link\": \"https://www.frontiersin.org/articles/10.3389/fnmol.2021.695937/pdf\", \"explanation\": \"The paper does not address the claim that mucopolysaccharidosis III and GM1 gangliosidosis are comorbid conditions. It discusses these conditions separately in the context of gene therapy without suggesting any comorbidity.\"}, {\"title\": \"Molecular mechanisms of cell death: recommendations of the Nomenclature Committee on Cell Death 2018\", \"authors\": [{\"name\": \"Lorenzo Galluzzi\", \"hIndex\": 141}, {\"name\": \"Ilio Vitale\", \"hIndex\": 58}, {\"name\": \"Stuart A. Aaronson\", \"hIndex\": 116}, {\"name\": \"John Abrams\", \"hIndex\": 47}], \"link\": \"https://www.nature.com/articles/s41418-017-0012-4.pdf\", \"explanation\": \"Paper was determined to be not relevant to the claim.\"}], \"inaccessiblePapers\": [], \"explanation\": \"The claim that Mucopolysaccharidosis III and GM1 gangliosidosis are comorbid conditions suggests that these two lysosomal storage disorders (LSDs) frequently occur together in patients. The provided evidence from the paper 'Lysosomal Storage Disorders in the Newborn' by Staretz\\u2010Chacham et al. does not directly address the comorbidity of these two specific conditions. The excerpts mention GM1 gangliosidosis in the context of developmental delay and cardiomyopathy, but there is no mention of Mucopolysaccharidosis III or any indication that these two conditions are linked or occur together in patients. The paper's relevance score of 0.2 and a score of 0.4775 suggest that the evidence is not highly pertinent to the claim.\\n\\nFurthermore, the paper primarily discusses the presentation of GM1 gangliosidosis and other LSDs in newborns, focusing on symptoms like developmental delay and cardiomyopathy. It does not provide any data or discussion on the co-occurrence of GM1 gangliosidosis with Mucopolysaccharidosis III. The lack of direct evidence or mention of comorbidity between these two conditions in the paper suggests that the claim is not supported by the provided evidence.\\n\\nGiven the absence of specific evidence linking Mucopolysaccharidosis III and GM1 gangliosidosis as comorbid conditions in the provided paper, the claim is not supported. The paper does not address the claim directly, nor does it provide any indirect evidence that could suggest a comorbid relationship. Therefore, the claim rating is -5, indicating that the claim is unsupported by the current evidence.\", \"claimRating\": -5, \"usage_stats\": {\"prompt_tokens\": 423, \"completion_tokens\": 352, \"total_tokens\": 775, \"total_cost\": 0.0046}}"
}